Abstract
Objective To study the effect and safety of entecavir on HBeAg positive hepatitis B virus (HBV) infection. Methods A total of 120 patients with HBeAg positive HBV were selected as research objects, and were randomly divided into study group and control group. Patients in study group were treated with entecavir, patients in control group were treated with adefovir dipivoxil. Results The negative conversion rate of HBV-DNA in study group was significantly higher than that in control group at every stage of treatment (P<0.05). After 12, 24 and 48 weeks of treatment, the HBeAg conversion rate in study group was significantly higher than that in control group (all P<0.05). The liver improvement of the patients in study group were significantly superior to those in control group at ever stage of treatment (P<0.05). The incidence of adverse reactions of study group was significantly lower than that of control group (P<0.05). Conclusions Entecavir antiviral therapy for HBeAg positive chronic active HBV can effectively improve the therapeutic effect, which is superior to adefovir dipivoxil. It is worthy of promotion and application clinically. Key words: Entecavir; Adefovir dipivoxil; Hepatitis B virus; Clinical observation; Security
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
